Second Circuit Affirms HHS Rejection of Direct Copayment Assistance under Anti-kickback Statute

By Conor Duffy & Guest Contributor on September 20, 2022

Posted in False Claims Act, Fraud and Abuse, Government Enforcement, Hospitals and Health Systems, Pharmaceuticals and Biologics

Below is an excerpt of a contributed article co-authored with Robinson+Cole Business Litigation Group lawyer Ben Daniels published in Physicians Practice on September 16, 2022.

On July 25, 2022, the U.S. Court of Appeals for the Second Circuit rejected an appeal brought by Pfizer, Inc. in a case that examines whether a “corrupt” intent is…

DOJ Reaches Settlement with Patient Assistance Foundation Resolving Allegations of FCA Violations

By Nathaniel Arden on January 28, 2020

Posted in Department of Justice, False Claims Act, Fraud and Abuse, Government Enforcement, Medicare and Medicaid, Office of Inspector General, Pharmaceuticals and Biologics

On January 21, 2020, the Department of Justice (DOJ) announced a $3 million settlement with Patient Services, Inc. (PSI) to resolve allegations of False Claims Act (FCA) violations. The DOJ alleged that PSI enabled three pharmaceutical companies to pay kickbacks to patients by funneling money to patients taking drugs manufactured by those same pharmaceutical companies. In addition to the $3 million, PSI has entered into a three-year integrity agreement with Health and Human Services’s Office of the Inspector General. The settlement involved no determination of liability.
Continue Reading DOJ Reaches Settlement with Patient Assistance Foundation Resolving Allegations of FCA Violations

Health Law Diagnosis

pharmaceutical

Second Circuit Affirms HHS Rejection of Direct Copayment Assistance under Anti-kickback Statute

DOJ Reaches Settlement with Patient Assistance Foundation Resolving Allegations of FCA Violations

Topics

Archives